A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.

Inovio spinout Geneos goes independent with a $10.5 million first-round financing for R&D in neoantigen-targeting cancer immunotherapies.

Japanese pharma Daiichi Sankyo is looking to boost its research focus with a series of changes across its R&D.

The data show smoking reductions occurred within two days of treatment, sending the nanocap’s stock up as much as 90% in premarket trading.

Thermo Fisher halted DNA sequencer sales in western China after reports the genetic sequencers were used to power a state DNA surveillance program.

Propeller Health is partnering up with Orion to bring its digital inhaler platform to the Finnish drugmaker’s Easyhaler line of products.

Rutgers University scientists have made a surprising discovery that could lead to improved methods for diagnosing and treating human genetic diseases.

Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.

Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.